Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 25:9:e1948.
doi: 10.31661/gmj.v9i0.1948. eCollection 2020.

Prognostic Impact of Monocyte to Lymphocyte Ratio in Clinical Outcome of Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Masoud Nouri-Vaskeh  1   2 , Mohammad Mirza-Aghazadeh-Attari  3 , Fariba Pashazadeh  4   5 , Saber Azami-Aghdash  6 , Hadi Alizadeh  7 , Parnia Pouya  7 , Monireh Halimi  8 , Golamreza Jadideslam  9 , Mohammad Zarei  10   11
Affiliations
Review

Prognostic Impact of Monocyte to Lymphocyte Ratio in Clinical Outcome of Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Masoud Nouri-Vaskeh et al. Galen Med J. .

Abstract

Background: Lymphocyte to monocyte ratio (LMR) is a surrogate marker of systemic inflammation which is shown to be related to the patient's survival in multiple malignancies. An important implication of this marker potentially is neoplasms in which there is no correlation between prognosis and histopathological staging and also has no reliable chemical markers associated with prognosis. Herein, this meta-analysis aimed to investigate the prognostic role of LMR in patients with hepatocellular carcinoma (HCC).

Materials and methods: In the current systemic review and meta-analysis, we conducted a systemic search of databases and indexing sources, including PubMed, EMBASE, Cochrane, Scopus, and ProQuest up to May 2019 toinclude studies on the prognostic significance of LMR on patients with HCC. Overall survival (OS), disease-free survival (DFS) and recurrence-free survival (RFS) values were extracted from the studies and analyzed. The pooled hazard ratio with a 95% confidence interval was explored to identify the prognostic value of the LMR in the survival of the patients with HCC.

Results: A total of 12 studies with a total sample size of 3750 cases were included. There was significant heterogeneity among the studies; therefore, subgroup analysis was also performed. Overall analysis regarding OS showed an insignificant relationship between LMR and patient's prognosis, dividing to subgroups based on LMR cut-offs did not yield any significant result, subgroup analysis for RFS founded statistically significant results and LMR was significantly related to DFS.

Conclusion: High LMR was associated with increased DFS and RFS, in return this association was not observed for OS.

Keywords: Disease-Free Survival; Hepatocellular Carcinoma; Liver Neoplasm; Lymphocyte to Monocyte Ratio; Survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure 2
Figure 2
Figure 3
Figure 3
Figure 4
Figure 4
Figure 5
Figure 5
Figure 6
Figure 6
Supplementary Figure 1
Supplementary Figure 1
Supplementary Figure 2
Supplementary Figure 2
Supplementary Figure 3
Supplementary Figure 3
Supplementary Figure 4
Supplementary Figure 4
See this image and copyright information in PMC

References

    1. Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1. - PMC - PubMed
    1. Yu LX, Ling Y, Wang HY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis Oncol. 2018;2(1):6. - PMC - PubMed
    1. Volcic M, Karl S, Baumann B, Salles D, Daniel P, Fulda S. et al. NF-κB regulates DNA double-strand break repair in conjunction with BRCA1-CtIP complexes. Nucleic Acids Res. 2012;40(1):181–95. - PMC - PubMed
    1. Taniguchi K, Karin M. NF-kappaB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18(5):309–24. - PubMed
    1. Adam JK, Odhav B, Bhoola KD. Immune responses in cancer. Pharmacol Ther. 2003;99(1):113–32. - PubMed

LinkOut - more resources